GRDX Key Statistics, Chart & Performance
The current stock price of GRDX is 3.1 USD.
GRDX Latest News, Press Relases and Analysis
GRDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.46 | 391.80B | ||
| AMGN | AMGEN INC | 14.57 | 171.60B | ||
| GILD | GILEAD SCIENCES INC | 15 | 152.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.09 | 114.92B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.44 | 77.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.8 | 52.61B | ||
| INSM | INSMED INC | N/A | 41.49B | ||
| NTRA | NATERA INC | N/A | 31.51B | ||
| BIIB | BIOGEN INC | 10.39 | 25.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.69 | 21.24B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.73 | 18.57B |
Related stock screener links
About GRDX
Company Profile
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The firm is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The firm is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
Company Info
GRIDAI TECHNOLOGIES CORP
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
Employees: 2
Phone: 15615897020
GRIDAI TECHNOLOGIES CORP / GRDX FAQ
What does GRDX do?
Entero Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The firm is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The firm is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
What is the current price of GRDX stock?
The current stock price of GRDX is 3.1 USD. The price decreased by -0.96% in the last trading session.
Does GRIDAI TECHNOLOGIES CORP pay dividends?
GRDX does not pay a dividend.
How is the ChartMill rating for GRIDAI TECHNOLOGIES CORP?
GRDX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does GRIDAI TECHNOLOGIES CORP belong to?
GRIDAI TECHNOLOGIES CORP (GRDX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for GRDX stock?
GRIDAI TECHNOLOGIES CORP (GRDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.09).
GRDX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GRDX.
GRDX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GRDX. GRDX may be in some trouble as it scores bad on both profitability and health.
GRDX Financial Highlights
Over the last trailing twelve months GRDX reported a non-GAAP Earnings per Share(EPS) of -11.09. The EPS increased by 76.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.48% | ||
| ROE | -31.45% | ||
| Debt/Equity | 0.01 |